



### CDC Institutional Biosafety Committee (IBC) Meeting Minutes

Date: September 19, 2025  
Time: 10:30 AM – 12:00 PM  
Location: MS Teams meeting

Member	Attendance	Member	Attendance
1. NCEZID/DVBD1	<input type="checkbox"/>	13. NCEZID/DCLSR2	<input checked="" type="checkbox"/>
2. NCIRD/DVD	<input checked="" type="checkbox"/>	14. IOD/OLSS3	<input type="checkbox"/>
3. NCEZID/DHCPP1	<input checked="" type="checkbox"/>	16. NCEZID/DCLSR3	<input checked="" type="checkbox"/>
4. IOD/OLSS1	<input checked="" type="checkbox"/>	17. NCEZID/OD	<input checked="" type="checkbox"/>
5. OCOO/OSSAM/OHC	<input type="checkbox"/>	18. IOD/OLSS4	<input checked="" type="checkbox"/>
6. NCEZID/DVBD2	<input checked="" type="checkbox"/>	19. NCHHSTP/DHP2	<input checked="" type="checkbox"/>
7. IOD/OLSS2	<input type="checkbox"/>	20. Outside Member/Atlanta1	<input type="checkbox"/>
8. NCHHSTP/DHP1	<input checked="" type="checkbox"/>	21. Outside Member/Atlanta2	<input checked="" type="checkbox"/>
9. NCHHSTP/DTE	<input type="checkbox"/>	22. Outside Member/Fort Collins	<input checked="" type="checkbox"/>
10. NCIRD/ID	<input type="checkbox"/>	23. Outside Member/Puerto Rico	<input checked="" type="checkbox"/>
11. NCIRD/CORVD	<input checked="" type="checkbox"/>	24. CDC/GHC/OD	<input checked="" type="checkbox"/>
12. NCEZID/DCLSR1	<input checked="" type="checkbox"/>	Visitor(s)	4

#### Agenda

1. Welcome from the Chair
2. Review and approval of the Aug 15, 2025 Meeting Minutes.
3. Review of protocols:
  1. IBC-2025-251 Renewal
  2. IBC-2025-264 Original
  3. IBC-2025-266 Original
  4. IBC-2025-267 Renewal
  5. IBC-2025-268 Renewal
  6. IBC-2025-270 Renewal
4. Other Business:

#### Principal Discussion

- Quorum confirmed.
- Meeting called to order at 10:27 am
- Welcome from the Chair
- Review and approval of the August 15, 2025 meeting summary. Approved as written.

#### Review of IBC Registration

1. IBC-2025-251 Renewal  
General Project Description: This project will utilize publicly available, well-characterized, and curated 'CDC and FDA Antimicrobial Resistance Isolate Bank (AR Bank)' bacterial isolates with known public health

significance. DNA extracted from these isolates will be used to clone genes associated with antimicrobial resistance into a standard laboratory-strain background (E. coli K12 and B derivatives) using commercially available vectors (pCR-II, pET101/D-TOPO). The resulting transformed bacteria will undergo enzymatic assessment by purification of expressed proteins and susceptibility testing against a fixed panel of clinical drugs using reference broth microdilution.

Approximate percentage of the viral genome used: N/A

Applicable Sec of NIH Guidelines: III-F-4, III-F-8

Required biological containment level for the work to be implemented: BSL-2

Committee Action: Approve as written.

2. IBC-2025-264 Original

General Project Description: Enterovirus (EV) and parechovirus (PeV) are small nonenveloped positive-sensed RNA viruses belonging to the picornavirus family. They are primarily transmitted through the fecal-oral route and respiratory secretions and can cause a wide spectrum of diseases in humans, particularly in infants and young children. Some strains such as poliovirus, EV-D68 or PeV-A3 can cause neurovirulence resulting in acute flaccid myelitis. Currently only vaccines against poliovirus are in use and no therapeutics are available to treat acute flaccid myelitis. The cellular entry and replication processes of many EV and PeV strains remain largely unknown. Elucidating the viral pathogenesis will help to develop strategies for diagnosis, prevention and treatment of EV and PeV infections.

Approximate percentage of the viral genome used: N/A

Applicable Sec of NIH Guidelines: III-E, III-F.

Required biological containment level for the work to be implemented: BSL2

Committee Action: Approve as written.

3. IBC-2025-266 Original

General Project Description: We are utilizing SARS-CoV-2 reporter viruses, including nano-luciferase-tagged variants, as well as SARS-CoV-2 mRNA vaccines obtained from commercial sources, internal teams, or external collaborators for research on animal pathogenicity, transmission, antiviral assessment, and immunization.

Approximate percentage of the viral genome used: >2/3

Applicable Sec of NIH Guidelines: III-D-1a, III-D-2a, III-D-3a, III-D-4b

Required biological containment level for the work to be implemented: BSL2, BSL3

General Points discussed:

- Section 2.9: Please change it to "Yes" since this research involves using mRNA vaccine.
- Section 3: IACUC protocols (#3340 and #3380) were mentioned in Section 1.3, however, there is no IACUC registration numbers were listed in section 3. Please complete all fields in subsection 3.3

Committee Action: Approve with changes.

4. IBC-2025-267 Renewal

General Project Description: The goals of this research proposal is to develop reverse genetic systems for paramyxoviruses in order to study replication, pathogenesis, transmission, and to develop potential vaccines against such pathogenic viruses.

Approximate percentage of the viral genome used: >2/3

Applicable Sec of NIH Guidelines: III-D-1a, III-D-1b, III-D-1c, III-D-2-a, III-D-3-a, III-D-3-b, III-D-3-c, III-D-4-b

Required biological containment level for the work to be implemented: BSL-2, BSL-3, BSL-4

Committee Action: Approve as written.

5. IBC-2025-268 Renewal

General Project Description: The primary objective of smallpox bioterrorism preparedness is to save lives if smallpox somehow re-emerges. This includes the development of antiviral strategies. In 2018, the

antiviral TPOXX (tecovirimat or ST-246) was licensed by FDA for smallpox treatment. At that time FDA requested additional screening in vitro against variola virus isolates containing differences in the target protein amino acid sequence. These data increase the confidence in the effectiveness of TPOXX as a medical countermeasure and would identify any possible limitations of this medical countermeasure, informing policy guidance on effective use.

Approximate percentage of the viral genome used: <1/2

Applicable Sec of NIH Guidelines: III-D-1a, III-D-2a, III-D-3a

Required biological containment level for the work to be implemented: BSL-2

Committee Action: Approve as written.

6. IBC-2025-270 Renewal

General Project Description: The purpose of this study is to express and purify SARS-CoV-2 viral/host recombinant proteins in mammalian cells for downstream analytical and biochemical characterizations using advanced mass spectrometry and proteomics techniques.

Approximate percentage of the viral genome used: <1/2

Applicable Sec of NIH Guidelines: III-D-2a,

Required biological containment level for the work to be implemented: BSL-2

Committee Action: Approve as written.

## Other Business

- IBC-IACUC collaboration was discussed for the awareness of future discussion.
- Meeting adjourned at 11:42 am

Reynolds M.  
Salerno -S

Digitally signed by  
Reynolds M. Salerno -

S

Date: 2026.01.06  
16:26:47 -05'00'

---

Reynolds M Salerno, PhD

Director, Office of Laboratory Systems and Response